| Bioactivity | ALK4290 dihydrochloride (AKST4290 dihydrochlorid) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a Ki of 3.2 nM for hCCR3[1]. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism[2][3]. |
| Name | ALK4290 dihydrochloride |
| CAS | 1372127-19-9 |
| Formula | C27H36Cl3N5O3 |
| Molar Mass | 584.97 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Samanta A, te, al. Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. Asia Pac J Ophthalmol (Phila). May-Jun 2020; 9(3):250-259. [2]. NIVENS MC, et, al. Use of ccr3-inhibitors. US20130261153A1. |
ALK4290 dihydrochloride
CAS: 1372127-19-9 F: C27H36Cl3N5O3 W: 584.97
ALK4290 dihydrochloride (AKST4290 dihydrochlorid) is a potent and orally active CCR3 inhibitor extracted from patent US2
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.